Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Adjuvant Capital
BioCentury | Nov 7, 2023
Finance
Nov. 6 Financial Roundup: Cargo aims for $300M NASDAQ listing
Plus: Terremoto raises B round and updates from Engine, Memo, ImmuXell, Longbio and Ausper
BioCentury | Oct 12, 2023
Politics, Policy & Law
Oct. 11 Quick Takes: European Parliament proposes amendments to pharma legislation
Plus: Early stop for Novo’s kidney outcomes study of semaglutide; Agomab raises $100M series B; and updates from MinervaX, FDA, ARPA-H, Tempest, Kanvas-Federation Bio
BioCentury | Oct 9, 2023
Regulation
Oct. 9 Quick Takes: Setback for Alnylam’s amyloidosis program
Plus: Pfizer’s Bourla posts message of support for Israel, and updates from AnaptysBio, AstronauTx, LimmaTech, GSK, Zhifei and Pixelgen
BioCentury | Apr 27, 2023
Finance
April 27 Finance Quick Takes: Therini raises $36M A for fibrin-targeted therapies
Plus: Zura raises $80M, adds bifunctional asset in Lilly deal and updates from Foresite Diagnostics, Adcentrx, Pattern, Antiva and Mezzion
BioCentury | Feb 15, 2023
Deals
Feb. 15 Quick Takes: Emergent deal to grow Bavarian Nordic footprint in U.S., Europe
Plus: Maxion raises series A to develop mAbs against ion channels, GPCRs and updates from Arrowhead, Moderna, Galera, Codagenix, Nanite
BioCentury | Mar 25, 2022
Finance
Finding crack in IPO window, AN2 prices at parity with last private round
No step-up for single-asset AN2 as it goes public in preparation for pivotal study in lung disease
BioCentury | Feb 11, 2022
Deals
Feb. 10 Quick Takes: RA, Adjuvant ready Curevo to take on Shingrix with $60M A round
Seagen slides on guidance, and updates from Arkuda, Altesa, Aeglea, Congruence, 1859 and more
BioCentury | Jan 8, 2022
Deals
Jan. 7 Quick Takes: AZ adds another amyloidosis mAb via Neurimmune deal
Plus: a16z’s $9B in new funds earmarks cash for bio, and updates from Virtue, AN2, Ultragenx-Regeneron and more
BioCentury | Nov 3, 2021
Product Development
Nov. 2 Quick Takes: Pharmas collaborating on digital endpoint
Plus Comirnaty & Lumakras revenues, venture money for Aculys, Cambridge Epigenetix, Antiva and more
BioCentury | Sep 18, 2021
Deals
Sept. 17 Quick Takes: Clinical hold sinks Protagonist shares
Biocon partners with Serum Institute, plus Santé’s $260M fund, IASO Bio’s $108M series C, Everest in $12M renal deal and more
Items per page:
1 - 10 of 22